14 June 2019

Hypercholesterolemia is a major risk factor for cardiovascular disease. Statins are the most widely used cholesterol-lowering drugs. However, despite treatment with statins, many patients with elevated cholesterol levels will still develop cardiovascular disease. Currently it is apparent that not only cholesterol but also the immune system plays an important role in the development of atherosclerosis, but how cholesterol and the immune system interact is still unravelled.

Siroon Bekkering, theme Vascular damage, with colleagues from Amsterdam and Rotterdam investigated the activity of part of the immune system in individuals with and without high cholesterol levels. It appeared that specific immune cells in the blood (‘monocytes’) were more activated in patients with high cholesterol levels than in individuals with normal cholesterol levels; these cells produced more inflammatory molecules that are important in the development of cardiovascular disease. Subsequently, the patients with high cholesterol were treated with statins to lower their cholesterol levels and the same measurements were repeated three months later. Importantly, despite cholesterol lowering, the hyperactivity of the immune cells did not decrease at all.

Niels Riksen, theme Vascular damage, coordinator of the project states that “we thus observed that these immune cells appear to ‘remember’ the high cholesterol, they once were exposed to. The finding that monocytes can remember previous exposures has only recently been discovered, and has been termed ‘trained immunity’, and this is the first study to demonstrate this in patients.” According to Riksen it would be interesting to investigate now how long this memory lasts and also whether the hyperactivity of the monocytes can be reduced by other drug types, such as anti-inflammatory drug.

Source: Bekkering S, Stiekema LCA, Bernelot Moens S, Verweij SL, Novakovic B, Prange K, Versloot M, Roeters van Lennep JE, Stunnenberg H, de Winther M, Stroes ESG, Joosten LAB, Netea MG, Riksen NP. Treatment with statins does not revert trained immunity in patients with familial hypercholesterolemia. Cell Metab 2019 [in press]

Related news items


Researchers investigate how stem cells affect the immune system

18 February 2020

RIMLS researchers Irma Joosten and Renate van der Molen, participating in an European study into the treatment of brain damage in premature babies. Is it possible to limit or even partly repair the damage with stem cells? They focus primarily on the effect of those stem cells on the immune system.

read more

Lowlands Science call for projects

17 February 2020

Researchers pay attention! Lowlands is looking for research teams to participate in Lowlands Science 2020. It’s a great way to reach a large audience, do unique experiments with and on them, and to have a memorable experience with your colleagues.

read more

Five ZonMw ‘Off Road’ grants for Radboudumc researchers

17 February 2020

Benoit Besson, Annemarie Boleij, Jonne Doorduin, Jorik Nonnekes and Sara Roig Merino have each received an ZonMw ‘Off Road’ grant of €100,000. The grants are intended for biomedical health researchers who dare to go off the beaten track in their search for new insights and unexpected breakthroughs.

read more

Dutch Kidney Foundation PhD grant for Johan van der Vlag and Tom Nijenhuis

14 February 2020

Johan van der Vlag and Tom Nijenhuis, theme Renal disorders, received this grant for their joint research project “Targeting a novel paracrine signaling pathway between glomerular endothelium and podocytes to treat glomerular injury”.

read more

Health Valley 10 - 11 - 12 March

13 February 2020

For three days, professionals from healthcare, health innovation, business, education and science will come together to share their knowledge and experiences about the healthcare of the future.

read more

KNAW Early Career Award for Geert Litjens

13 February 2020

Twelve young researchers received the Early Career Award from KNAW on 4 february. One of them is RIHS researcher Geert Litjens. The Award is aimed at researchers in the Netherlands at the start of their career who are capable of developing innovative and original research ideas.

read more